Is Bolt Biotherapeutics Stock a good buy in 2024, according to Wall Street analysts?
The consensus among 2 Wall Street analysts covering (NASDAQ: BOLT) stock is to Hold BOLT stock.
Out of 2 analysts, 0 (0%) are recommending BOLT as a Strong Buy, 0 (0%) are recommending BOLT as a Buy, 2 (100%) are recommending BOLT as a Hold, 0 (0%) are recommending BOLT as a Sell, and 0 (0%) are recommending BOLT as a Strong Sell.
According to 2 Wall Street analysts that have issued a 1 year BOLT price target, the average BOLT price target is $1.25, with the highest BOLT stock price forecast at $1.50 and the lowest BOLT stock price forecast at $1.00.
On average, Wall Street analysts predict that Bolt Biotherapeutics's share price could reach $1.25 by May 15, 2025. The average Bolt Biotherapeutics stock price prediction forecasts a potential upside of 86.57% from the current BOLT share price of $0.67.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.